Publication | Closed Access

Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial

Intermittent VismodegibMedicinePharmacotherapyDermatologyMultiple Basal-cell CarcinomasCancer TreatmentOncologyRadiation OncologySkin Cancer